Business News • PR NewsWire • BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

BERGEN, Norway, April 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces preclinical data strengthening bemcentinib's broad potential in reversing...

View More : https://www.prnewswire.com:443/news-releases/bergenbio-preclinical-data-presented-at-aacr-reinforces-bemcentinibs-potent...

Releted News by prnewswire

Global Environmental Management Solutions and TODAQ announce 1st cross border supply chain shipment on the decentralised TODA protocol

Moberg Pharma Gives Notice of Early Redemption of Bonds With ISIN SE0007953989

Greenlight Energy enters into $5,000,000 Credit Facility with V3 Commodities Group

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results